Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Drop in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 49,800 shares, a decline of 42.4% from the September 30th total of 86,400 shares. Based on an average daily trading volume, of 70,900 shares, the short-interest ratio is presently 0.7 days. Approximately 1.0% of the company’s shares are short sold. Approximately 1.0% of the company’s shares are short sold. Based on an average daily trading volume, of 70,900 shares, the short-interest ratio is presently 0.7 days.

Aprea Therapeutics Stock Down 3.4%

Aprea Therapeutics stock opened at $1.40 on Friday. Aprea Therapeutics has a 52-week low of $1.31 and a 52-week high of $5.00. The firm has a fifty day moving average of $1.50 and a 200-day moving average of $1.64. The firm has a market capitalization of $8.16 million, a P/E ratio of -0.60 and a beta of 1.30.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.24. Aprea Therapeutics had a negative net margin of 1,645.01% and a negative return on equity of 78.90%. The company had revenue of $0.12 million during the quarter. On average, research analysts expect that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $15.50.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.